Evidence map›Paper›PMID 35560527›Full record

ArticleClinical and translational medicine2022

Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage.

Jeffrey Molendijk, Cathryn M Kolka, Henry Cairns, Sandra Brosda, Ahmed Mohamed, Alok K Shah, Ian Brown, Mark P Hodson, Thomas Hennessy, Guanghao Liu and 9 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Pan-cancer analysis andFrontiers in oncology · 2023
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Jeffrey MolendijkThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0001-6575-504X
Cathryn M KolkaPrecision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0002-6636-7062
Henry CairnsPrecision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0002-4275-0913
Sandra BrosdaThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0002-0867-6166
Ahmed MohamedThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0001-6507-5300
Alok K ShahThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0002-2687-1168
Ian BrownEnvoi Pathology, Herston, Australia.ORCID 0000-0001-6329-2547
Mark P HodsonSchool of Pharmacy, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0002-5436-1886
Thomas HennessyThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0002-5717-6774
Guanghao LiuPrecision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.
Thomas StollPrecision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0002-6275-3433
Renee S RichardsPrecision and Systems Biomedicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.ORCID 0000-0002-8911-8966
Michael GartsideThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
Kalpana PatelThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.
Nicholas J ClemonsDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0001-9283-9978
Wayne A PhillipsDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0002-7961-638X
Andrew BarbourThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0002-0991-7662
Johan A WesterhuisSwammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-6747-9779
Michelle M HillThe University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Australia.ORCID 0000-0003-1134-0951
Translational Research Institute · AUQIMR Berghofer Medical Research Institute · AUThe University of Melbourne · AUEnvoi Specialist Pathologists · AUThe University of Queensland · AUUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk of esophageal adenocarcinoma (EAC) is associated with gastro-esophageal reflux disease (GERD) and obesity. Lipid metabolism-targeted therapies decrease the risk of progressing from Barrett's esophagus (BE) to EAC, but the precise lipid metabolic changes and their roles in genotoxicity during EAC development are yet to be established.

methodsEsophageal biopsies from the normal epithelium (NE), BE, and EAC, were analyzed using concurrent lipidomics and proteomics (n = 30) followed by orthogonal validation on independent samples using RNAseq transcriptomics (n = 22) and immunohistochemistry (IHC, n = 80). The EAC cell line FLO-1 was treated with FADS2 selective inhibitor SC26196, and/or bile acid cocktail, followed by immunofluorescence staining for γH2AX.

resultsMetabolism-focused Reactome analysis of the proteomics data revealed enrichment of fatty acid metabolism, ketone body metabolism, and biosynthesis of specialized pro-resolving mediators in EAC pathogenesis. Lipidomics revealed progressive alterations (NE-BE-EAC) in glycerophospholipid synthesis with decreasing triglycerides and increasing phosphatidylcholine and phosphatidylethanolamine, and sphingolipid synthesis with decreasing dihydroceramide and increasing ceramides. Furthermore, a progressive increase in lipids with C20 fatty acids and polyunsaturated lipids with ≥4 double bonds were also observed. Integration with transcriptome data identified candidate enzymes for IHC validation: Δ4-Desaturase, Sphingolipid 1 (DEGS1) which desaturates dihydroceramide to ceramide, and Δ5 and Δ6-Desaturases (fatty acid desaturases, FADS1 and FADS2), responsible for polyunsaturation. All three enzymes showed significant increases from BE through dysplasia to EAC, but transcript levels of DEGS1 were decreased suggesting post-translational regulation. Finally, the FADS2 selective inhibitor SC26196 significantly reduced polyunsaturated lipids with three and four double bonds and reduced bile acid-induced DNA double-strand breaks in FLO-1 cells in vitro.

conclusionsIntegrated multiomics revealed sphingolipid and phospholipid metabolism rewiring during EAC development. FADS2 inhibition and reduction of the high polyunsaturated lipids effectively protected EAC cells from bile acid-induced DNA damage in vitro, potentially through reduced lipid peroxidation.

Indexed as

AdenocarcinomaBarrett EsophagusBile Acids and SaltsDNA DamageEsophageal NeoplasmsFatty Acid DesaturasesFatty AcidsHumansSphingolipidsBile Acids and SaltsFatty Acid DesaturasesFatty AcidsSphingolipidsBarrett's esophagusesophageal adenocarcinomaFADS2lipid desaturationlipid metabolism

Identifiers

PMID35560527
PMCPMC9099135
OpenAlexW4280523142

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.